{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 8,
    "verified": 7,
    "rejected": 1,
    "verification_rate": 0.875
  },
  "verified_evidence": [
    {
      "id": 1,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "supports_claim": true,
      "explanation": "The quote explicitly states that the randomized trial (NCT03722589) evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok), quadrivalent inactivated egg-based (IIV4), and cell culture-based (ccIIV4) vaccines. The document further clarifies that IIV4 includes Fluarix (as seen on page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent; ccIIV4: Cell culture based IIV'). Therefore, the quote directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 1 of the document: 'In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza'. This matches the quoted text in meaning and content, with only minor formatting differences (e.g., 'quad rival ent' vs 'quadrivalent').",
      "support_explanation": "The quote explicitly states that the randomized trial (NCT03722589) evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok), quadrivalent inactivated egg-based (IIV4), and cell culture-based (ccIIV4) vaccines. The document further clarifies that IIV4 includes Fluarix (as seen on page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent; ccIIV4: Cell culture based IIV'). Therefore, the quote directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote explicitly states that the randomized trial evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok), alongside quadrivalent inactivated egg-based (IIV4) and cell culture-based (ccIIV4) vaccines, confirming that Flublok (quadrivalent) was evaluated in the pivotal trial."
    },
    {
      "id": 2,
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit re-enrolled in Year 2 and new enrollees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "supports_claim": true,
      "explanation": "The quote provides explicit evidence that Flublok (RIV4, quadrivalent recombinant influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both used as comparator arms in the pivotal trial, with specific numbers of participants allocated to each. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 2 of the document, in the section describing participant allocation: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The numbers and structure match the quote, with only minor formatting differences (e.g., 'e-enrolled' vs 're-enrolled'). The factual content and participant allocation are preserved.",
      "support_explanation": "The quote provides explicit evidence that Flublok (RIV4, quadrivalent recombinant influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both used as comparator arms in the pivotal trial, with specific numbers of participants allocated to each. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote provides the actual allocation of participants to the Fluarix IIV4 (quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), showing that both vaccines were directly compared in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "supports_claim": true,
      "explanation": "The quote explicitly states that the study included quadrivalent inactivated egg-based (IIV4), cell culture-based (ccIIV4), and recombinant (RIV4) influenza vaccines. The document further clarifies that IIV4 includes Fluarix (as seen on page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent)'). RIV4 is identified as Flublok. Therefore, the quote directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote 'sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza' appears in the document on page 1. The wording is nearly identical, with only minor formatting differences (e.g., 'quad rival ent in activated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza'). The semantic content is preserved.",
      "support_explanation": "The quote explicitly states that the study included quadrivalent inactivated egg-based (IIV4), cell culture-based (ccIIV4), and recombinant (RIV4) influenza vaccines. The document further clarifies that IIV4 includes Fluarix (as seen on page 2: 'IIV4: In activated influenza vaccine (Flu zone or Fluarix\u00ae Quad rival ent)'). RIV4 is identified as Flublok. Therefore, the quote directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote confirms that the study included both the recombinant quadrivalent vaccine (Flublok) and the standard quadrivalent inactivated vaccine (IIV4, which includes Fluarix), supporting the claim of a direct evaluation."
    },
    {
      "id": 4,
      "quote": "Fluarix IIV4: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ccIIV4: Day 0 (n = 133), 1 m (n = 132), 6 m (n = 124); RIV4: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 85);",
      "supports_claim": true,
      "explanation": "The quote lists sample sizes for Fluarix IIV4 (standard-dose quadrivalent), ccIIV4, and RIV4 (Flublok quadrivalent) at Day 0, 1 month, and 6 months, showing that Flublok (RIV4) was evaluated alongside Fluarix (IIV4) in the pivotal trial. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 5 in the following form: 'mean (GM) fold rise of antibody titers (1 m/Day 0) from each of the four vacc groups were calculated for egg- and cell propagated vaccine viruses, and for 18 years (Flu zone IIV4 (n = 52), Fluarix IIV4 (n = 55), ccIIV4 (n = 133), RIV4 (n = 98))'. Additionally, on the same page, the 6-month numbers are given: '18-44 years (Flu zone IIV4 (n = 47), Fluarix IIV4 (n = 48), ccIIV4 (n = 124), RIV4 (n = 85))'. The numbers and vaccine groupings match the quote, though the quote combines both age groups' numbers for each timepoint, while the document lists them by age group. The factual content and sample sizes are preserved.",
      "support_explanation": "The quote lists sample sizes for Fluarix IIV4 (standard-dose quadrivalent), ccIIV4, and RIV4 (Flublok quadrivalent) at Day 0, 1 month, and 6 months, showing that Flublok (RIV4) was evaluated alongside Fluarix (IIV4) in the pivotal trial. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote lists the sample sizes for Fluarix IIV4 (standard-dose quadrivalent), ccIIV4, and RIV4 (Flublok quadrivalent), demonstrating that Flublok was evaluated against Fluarix in the trial."
    },
    {
      "id": 5,
      "quote": "Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).",
      "supports_claim": true,
      "explanation": "The quote lists Fluarix IIV4 and RIV4 (Flublok quadrivalent) as separate arms in the trial, with participant numbers at each time point. This directly demonstrates that Flublok (RIV4) was evaluated against Fluarix (IIV4, a standard-dose quadrivalent vaccine) in the pivotal trial, as the claim asserts. No inference is required; the document explicitly shows both vaccines were included as comparators in the same study.",
      "presence_explanation": "The quote appears on page 6 of the document: '(n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).' The full context is: 'Flu zone IIV4: Day0 (n = 24), 1 m (n = 24), 6 m (n = 21); Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).' The numbers and vaccine arms match the quote, and the factual content is preserved.",
      "support_explanation": "The quote lists Fluarix IIV4 and RIV4 (Flublok quadrivalent) as separate arms in the trial, with participant numbers at each time point. This directly demonstrates that Flublok (RIV4) was evaluated against Fluarix (IIV4, a standard-dose quadrivalent vaccine) in the pivotal trial, as the claim asserts. No inference is required; the document explicitly shows both vaccines were included as comparators in the same study.",
      "original_relevance": "This quote further confirms that Flublok (RIV4) and Fluarix (IIV4) were both included as arms in the pivotal trial, supporting the claim of their direct evaluation."
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enrollees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "supports_claim": true,
      "explanation": "The quote lists the allocation of participants in the randomized trial, specifically showing that Fluarix (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were both included as comparator arms. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 2 of the document, in the following form: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The numbers and vaccine names match the quote to verify, with only minor formatting and spacing differences due to OCR and extraction. The factual content is preserved.",
      "support_explanation": "The quote lists the allocation of participants in the randomized trial, specifically showing that Fluarix (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were both included as comparator arms. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote lists the vaccine allocation for the randomized trial, showing that both Fluarix (quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were included as comparator arms, directly supporting the claim."
    },
    {
      "id": "comp_3",
      "quote": "Day 0 1 m 6 m 5 10 Fig. 2 | MN or HI Antibody responses to egg- and cell propagated vaccine viruses at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. Antibody titers from each of the four vaccine groups were presented as geometric mean titers (GMTs) with 95% confidence interval (CI) respectively for 18\u221244 years and 45\u221264 years age groups. Gray dots represented individual titers. Flu zone IIV4 18\u221244 years: Day 0 (n = 52), 1 m (n = 52), 6 m (n = 47); Flu zone IIV4 4564 years: Day 0 (n = 58), 1 m (n = 58), 6 m (n = 54); Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ccIIV4 18\u221244 years: Day 0 (n = 133), 1 m (n = 132), 6 m (n = 124); RIV4 18\u221244 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 85);",
      "supports_claim": true,
      "explanation": "The quote explicitly lists Fluarix IIV4 and RIV4 (Flublok Quadrivalent) as two of the four vaccine groups evaluated in the pivotal trial, with data presented for each. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). No inference is required; the document clearly shows both vaccines were included and compared in the trial.",
      "presence_explanation": "The quote appears on page 4 of the document, starting with 'Day 0 1 m 6 m 5 10 Fig. 2 | MN or HI Antibody responses to egg- and cell propagated vaccine viruses at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1.' The quote details the four vaccine groups: Flu zone IIV4, Fluarix IIV4, ccIIV4, and RIV4, with corresponding sample sizes for each time point and age group. The factual content, including the mention of Fluarix IIV4 (quadrivalent standard-dose) and RIV4 (Flublok Quadrivalent), is preserved.",
      "support_explanation": "The quote explicitly lists Fluarix IIV4 and RIV4 (Flublok Quadrivalent) as two of the four vaccine groups evaluated in the pivotal trial, with data presented for each. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). No inference is required; the document clearly shows both vaccines were included and compared in the trial.",
      "original_relevance": "This quote details the four vaccine groups compared in the trial, including Fluarix IIV4 (quadrivalent standard-dose) and RIV4 (Flublok Quadrivalent), confirming that these two vaccines were directly evaluated against each other."
    }
  ],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "acell culture based influenza vaccine (Flu cel vax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly identifies Flublok Quadrivalent (RIV4) as the recombinant influenza vaccine evaluated in the study, confirming its inclusion in the pivotal trial."
    }
  ],
  "model_used": "gpt-4.1"
}